Payment overview · 2025
General Payments
$1,304.73
65 reported records · 19 companies
Healthcare provider profile · identity verified
Edison N Tan, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · CLEARWATER, FL · NPI 1962475533
Verified facts
What the public records show
CMS Open Payments records show Edison N Tan, M.D. received $1,304.73 in general payments during 2025 across 65 reported records.
ABBVIE INC. accounted for 21.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 273 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $277.30 | 21.2% | 15 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $166.43 | 12.8% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $164.61 | 12.6% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $107.31 | 8.2% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $99.06 | 7.6% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $74.33 | 5.7% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $65.97 | 5.1% | 4 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $46.98 | 3.6% | 3 | 2025 |
| Renalytix AI, Inc. | Unresolved — no canonical attribution shown | $44.37 | 3.4% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $37.39 | 2.9% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $35.60 | 2.7% | 2 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $27.33 | 2.1% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $25.88 | 2.0% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $25.28 | 1.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $24.73 | 1.9% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.12 | 1.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.55 | 1.7% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $20.46 | 1.6% | 1 | 2025 |
| TMS NeuroHealth Centers Inc. | Unresolved — no canonical attribution shown | $16.03 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,304.73 | 65 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $182.32 | 9 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $180.85 | 9 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $166.43 | 8 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $107.31 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $99.06 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $76.62 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $56.40 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $54.11 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $54.11 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $51.97 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $51.64 | 2 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $48.71 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $48.10 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $47.42 | 2 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $46.98 | 3 | 2025 |
Source payment records
|
|||||
| KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT Normalized: kidneyintelx blood collection convenience kit |
Device | Renalytix AI, Inc. | $44.37 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $37.39 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $35.60 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $28.74 | 3 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $27.33 | 1 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $27.33 | 1 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $25.88 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $25.28 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $24.73 | 1 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $23.12 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $22.55 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $21.04 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 2 Normalized: freestyle libre 2 |
Device | Abbott Laboratories | $20.46 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $20.22 | 1 | 2025 |
Source payment records
|
|||||
| TMS NeuroHealth Centers Inc. Normalized: tms neurohealth centers inc |
Device | TMS NeuroHealth Centers Inc. | $16.03 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.00 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 273 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 54 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 82 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
82 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
273 | 40 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 566 | 91 |
| Levothyroxine Sodium | Levothyroxine Sodium | 450 | 58 |
| Lisinopril | Lisinopril | 400 | 51 |
| Furosemide | Furosemide | 392 | 51 |
| Gabapentin | Gabapentin | 315 | 34 |
| Amlodipine Besylate | Amlodipine Besylate | 294 | 43 |
| Potassium Chloride | Potassium Chloride | 281 | 32 |
| Eliquis | Apixaban | 273 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 263 | 53 |
| Metoprolol Tartrate | Metoprolol Tartrate | 242 | 38 |
| Simvastatin | Simvastatin | 213 | 49 |
| Losartan Potassium | Losartan Potassium | 192 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 187 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 184 | 26 |
| Divalproex Sodium | Divalproex Sodium | 155 | 15 |
| Donepezil Hcl | Donepezil Hcl | 155 | 19 |
| Omeprazole | Omeprazole | 152 | 29 |
| Alprazolam | Alprazolam | 130 | 25 |
| Finasteride | Finasteride | 129 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 124 | 36 |
| Carvedilol | Carvedilol | 112 | 15 |
| Mirtazapine | Mirtazapine | 112 | 17 |
| Trazodone Hcl | Trazodone Hcl | 107 | 17 |
| Amiodarone Hcl | Amiodarone Hcl | 102 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 101 | 15 |
| Clonazepam | Clonazepam | 99 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 93 | 11 |
| Midodrine Hcl | Midodrine Hcl | 92 | 15 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 91 | 24 |
| Baclofen | Baclofen | 89 | suppressed |
| Levetiracetam | Levetiracetam | 88 | suppressed |
| Metformin Hcl | Metformin Hcl | 88 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 88 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 86 | 13 |
| Ozempic | Semaglutide | 82 | 14 |
| Spironolactone | Spironolactone | 81 | 11 |
| Sertraline Hcl | Sertraline Hcl | 77 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 76 | 11 |
| Meloxicam | Meloxicam | 75 | 15 |
| Memantine Hcl | Memantine Hcl | 75 | 12 |
| Xarelto | Rivaroxaban | 74 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 67 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 66 | 20 |
| Nifedipine Er | Nifedipine | 62 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 60 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 57 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 56 | suppressed |
| Jardiance | Empagliflozin | 54 | suppressed |
| Allopurinol | Allopurinol | 53 | suppressed |
| Prednisone | Prednisone | 53 | 23 |
| Buspirone Hcl | Buspirone Hcl | 52 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 51 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 49 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 48 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 46 | suppressed |
| Bumetanide | Bumetanide | 45 | suppressed |
| Famotidine | Famotidine | 45 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 45 | 12 |
| Morphine Sulfate Er | Morphine Sulfate | 45 | suppressed |
| Atenolol | Atenolol | 44 | suppressed |
| Lamotrigine | Lamotrigine | 43 | suppressed |
| Oxycontin | Oxycodone Hcl | 42 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 42 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 40 | 26 |
| Nystatin | Nystatin | 40 | 17 |
| Tramadol Hcl | Tramadol Hcl | 40 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 38 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 36 | 14 |
| Bethanechol Chloride | Bethanechol Chloride | 35 | suppressed |
| Calcitriol | Calcitriol | 35 | suppressed |
| Solu-Medrol | Methylprednisolone Sod Succ/Pf | 35 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 34 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 33 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 33 | 15 |
| Venlafaxine Hcl | Venlafaxine Hcl | 33 | suppressed |
| Celecoxib | Celecoxib | 29 | suppressed |
| Latanoprost | Latanoprost | 29 | suppressed |
| Acyclovir | Acyclovir | 28 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 28 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 28 | suppressed |
| Trimethoprim | Trimethoprim | 28 | suppressed |
| Azithromycin | Azithromycin | 27 | 24 |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 27 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 27 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 25 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 25 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 25 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | 15 |
| Temazepam | Temazepam | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Irbesartan | Irbesartan | 24 | suppressed |
| Minoxidil | Minoxidil | 24 | suppressed |
| Valsartan | Valsartan | 24 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 24 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 23 | 14 |
| Memantine Hcl Er | Memantine Hcl | 23 | suppressed |
| Cephalexin | Cephalexin | 22 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 18 |
| Ezetimibe | Ezetimibe | 22 | suppressed |
| Folic Acid | Folic Acid | 22 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 22 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 22 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 22 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Methocarbamol | Methocarbamol | 21 | suppressed |
| Secuado | Asenapine | 21 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | suppressed |
| Methotrexate | Methotrexate Sodium | 20 | suppressed |
| Methylprednisolone | Methylprednisolone | 20 | 13 |
| Nuplazid | Pimavanserin Tartrate | 20 | suppressed |
| Risperidone | Risperidone | 20 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 18 | suppressed |
| Ertapenem | Ertapenem Sodium | 18 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 17 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Levemir Flexpen | Insulin Detemir | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 12 |
| Nitroglycerin | Nitroglycerin | 17 | 15 |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Cefdinir | Cefdinir | 16 | 12 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 15 | suppressed |
| Ceftriaxone | Ceftriaxone In Is-Osm Dextrose | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Meropenem-0.9% Nacl | Meropenem-0.9% Sodium Chloride | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Timolol Maleate | Timolol Maleate | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 11 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Travoprost | Travoprost | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,304.73 · 65 records | ABBVIE INC. | AIRSUPRA, Arikayce, Brinsupri, CREON, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FREESTYLE LIBRE 2, General - Pain Management, JARDIANCE, KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT, KISUNLA, Kerendia, LEQVIO, LINZESS, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, RECORLEV, REPATHA, Rybelsus, TMS NeuroHealth Centers Inc., TRELEGY ELLIPTA, UBRELVY, VYALEV, Wegovy, XYOSTED, ZAVZPRET, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error